Apimeds Pharmaceuticals US I
13F holders, Q4 2025 (December 31)7holders −1
3new positions
4sold out
$1.64avg. 13F price*
At the end of Q4 2025, 7 institutions reported holding Apimeds Pharmaceuticals US I in their 13F filings, down 1 from Q3 2025. 3 opened new positions and 4 sold out. The largest holders were Hemenway Trust Co LLC ($449K), Vanguard Group Inc. ($97K) and Geode Capital Management, LLC ($57K).
- Company
- Apimeds Pharmaceuticals US I
- CUSIP
- 03771D102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $46K |
| Exits | 4 | $107K |
All 13F filers, Q3 2025 → Q4 2025: 55,925 shares bought and 60,208 shares sold, net −4,283 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Hemenway Trust Co LLC | 0.03% | Add +9.6% | 274,000 | $449K |
| Vanguard Group Inc. | 0.00% | No change | 58,992 | $97K |
| Geode Capital Management, LLC | 0.00% | Add +13.4% | 34,888 | $57K |
| Jane Street Group, LLC | 0.00% | New | 27,188 | $45K |
| UBS Group AG | 0.00% | New | 582 | $954 |
| Bank of America Corp. | 0.00% | Add +37.9% | 40 | $66 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 10 | $16 |
"% of holder's portfolio" is APIMEDS PHARMACEUTICALS US I's weight in each manager's 13F, not the share of Apimeds Pharmaceuticals US I the manager owns.